Roberto Pili

  • 10771 Citations
  • 51 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1990 2019

9 Citations (Scopus)

Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours'

Bartoloni, C., Guidi, L., Tricerri, A., Patriarca, F., Pili, R., Cursi, F., Canetta, M., Cappelli, A., Vangeli, M., Salvati, F. & Gambassi, G., 1992, In : Oncology. 49, 6, p. 426-430 5 p.

Research output: Contribution to journalArticle

Neoplasms
Blood Coagulation Disorders
Gastrointestinal Neoplasms
antithrombin III-protease complex
Non-Small Cell Lung Carcinoma
29 Citations (Scopus)

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II double-blinded, randomized study

Keizman, D., Zahurak, M., Sinibaldi, V., Carducci, M., Denmeade, S., Drake, C., Pili, R., Antonarakis, E. S., Hudock, S. & Eisenberger, M., Nov 1 2010, In : Clinical Cancer Research. 16, 21, p. 5269-5276 8 p.

Research output: Contribution to journalArticle

Prostate-Specific Antigen
Prostatic Neoplasms
Neutropenia
Population
Androgens
33 Citations (Scopus)

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Armstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V., Polikoff, J., Damber, J. E., Belkoff, L., Nordle, Ö., Forsberg, G., Carducci, M. A. & Pili, R., Dec 15 2013, In : Clinical Cancer Research. 19, 24, p. 6891-6901 11 p.

Research output: Contribution to journalArticle

Castration
Multicenter Studies
Prostatic Neoplasms
Biomarkers
Survival

Low-protein diet in cancer: Ready for prime time?

Pili, R. & Fontana, L., Jul 1 2018, In : Nature Reviews Endocrinology. 14, 7, p. 384-386 3 p.

Research output: Contribution to journalArticle

Protein-Restricted Diet
Diet
Diet Therapy
Neoplasms
Immune System
162 Citations (Scopus)

Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance

Gotink, K. J., Broxterman, H. J., Labots, M., De Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., Griffioen, A. W., Assaraf, Y. G., Pili, R., Peters, G. J. & Verheul, H. M. W., Dec 1 2011, In : Clinical Cancer Research. 17, 23, p. 7337-7346 10 p.

Research output: Contribution to journalArticle

Drug Resistance
sunitinib
Neoplasms
Cell Proliferation
Lysosomes
1 Citation (Scopus)

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

Batty, N., Yarlagadda, N. & Pili, R., Aug 1 2013, In : JNCCN Journal of the National Comprehensive Cancer Network. 11, 8, p. 911-915 5 p.

Research output: Contribution to journalArticle

Castration
Prednisone
Cyclophosphamide
Prostatic Neoplasms
docetaxel
42 Citations (Scopus)

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial

Rosenbaum, E., Zahurak, M., Sinibaldi, V., Carducci, M. A., Pili, R., Laufer, M., DeWeese, T. L. & Eisenberger, M. A., Jun 15 2005, In : Clinical Cancer Research. 11, 12, p. 4437-4443 7 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Matrix Metalloproteinase Inhibitors
Poisons
14 Citations (Scopus)

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

Gupta, N., Ustwani, O. A., Shen, L. & Pili, R., Feb 12 2014, In : OncoTargets and Therapy. 7, p. 223-234 12 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Pharmaceutical Preparations
Drug Approval
Phase III Clinical Trials
Phase II Clinical Trials
31 Citations (Scopus)

Mechanisms of action of tasquinimod on the tumour microenvironment

Raymond, E., Dalgleish, A., Damber, J. E., Smith, M. & Pili, R., Jan 2014, In : Cancer Chemotherapy and Pharmacology. 73, 1, p. 1-8 8 p.

Research output: Contribution to journalReview article

Tumor Microenvironment
Tumors
Myeloid Cells
Neoplasms
Immunosuppressive Agents
4 Citations (Scopus)

Mental disorders in obese patients with and without metabolic syndrome

Carpiniello, B., Pinna, F., Pili, R., Velluzzi, F. & Loviselli, A., Jan 1 2011, In : International Journal of Psychiatry in Medicine. 42, 4, p. 369-375 7 p.

Research output: Contribution to journalArticle

Mental Disorders
Abdominal Obesity
728 Citations (Scopus)

Methods in laboratory investigation: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor

Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S. & Martin, G. R., 1992, In : Laboratory Investigation. 67, 4, p. 519-528 10 p.

Research output: Contribution to journalArticle

Angiogenesis Inhibitors
Fibroblast Growth Factors
Basement Membrane
Heparin
Gels
11 Citations (Scopus)

Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

Ebos, J. M. L. & Pili, R., Jul 15 2012, In : Clinical Cancer Research. 18, 14, p. 3719-3721 3 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor A
Blood Vessels
Neoplasms
Appointments and Schedules
Endothelial Cells
8 Citations (Scopus)

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy

Tracz, A., Mastri, M., Lee, C. R., Pili, R. & Ebos, J. M. L., 2014, In : Journal of visualized experiments : JoVE. 86

Research output: Contribution to journalArticle

Nephrectomy
Renal Cell Carcinoma
Tumors
Cells
Disease Progression
16 Citations (Scopus)

Modeling the cost of management options for stage I nonseminomatous germ cell tumors: A decision tree analysis

Link, R. E., Allaf, M. E., Pili, R. & Kavoussi, L. R., 2005, In : Journal of Clinical Oncology. 23, 24, p. 5762-5773 12 p.

Research output: Contribution to journalArticle

Decision Trees
Decision Support Techniques
Costs and Cost Analysis
Drug Therapy
Nonseminomatous germ cell tumor
16 Citations (Scopus)

Modified synthesis and antiangiogenic activity of Linomide

Khan, S. R., Mhaka, A., Pili, R. & Isaacs, J. T., Feb 26 2001, In : Bioorganic and Medicinal Chemistry Letters. 11, 4, p. 451-452 2 p.

Research output: Contribution to journalArticle

Thermodynamic properties
Blood vessels
Microvessels
Blood Volume
Blood Vessels
15 Citations (Scopus)

Modulation of chemotherapeutic efficacy by vascular disrupting agents: Optimizing the sequence and schedule

Wang, E. S., Pili, R. & Seshadri, M., Mar 1 2012, In : Journal of Clinical Oncology. 30, 7, p. 760-761 2 p.

Research output: Contribution to journalLetter

Antineoplastic Combined Chemotherapy Protocols
Xanthones
Molecular Targeted Therapy
Statistical Data Interpretation
Angiogenesis Inhibitors
5 Citations (Scopus)

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer

Kalmuk, J., Folaron, M., Buchinger, J., Pili, R. & Seshadri, M., 2015, In : Oncotarget. 6, 27, p. 24376-24392 17 p.

Research output: Contribution to journalArticle

Multimodal Imaging
Blood Vessels
Prostatic Neoplasms
Neoplasms
Castration
5 Citations (Scopus)

Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial

Paller, C. J., Zhou, X. C., Heath, E. I., Taplin, M. E., Mayer, T., Stein, M. N., Bubley, G. J., Pili, R., Hudson, T., Kakarla, R., Abbas, M. M., Anders, N. M., Dowling, D., King, S., Bruns, A. B., Wagner, W. D., Drake, C. G., Antonarakis, E. S., Eisenberger, M. A., Denmeade, S. R. & 3 others, Rudek, M. A., Rosner, G. L. & Carducci, M. A., Jan 15 2018, In : Clinical Cancer Research. 24, 2, p. 306-315 10 p.

Research output: Contribution to journalArticle

Controlled Clinical Trials
Vitis
Prostatic Neoplasms
Placebos
Skin
35 Citations (Scopus)

Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells

Minelli, R., Cavalli, R., Ellis, L., Pettazzoni, P., Trotta, F., Ciamporcero, E., Barrera, G., Fantozzi, R., Dianzani, C. & Pili, R., Nov 20 2012, In : European Journal of Pharmaceutical Sciences. 47, 4, p. 686-694 9 p.

Research output: Contribution to journalArticle

Camptothecin
Human Activities
Prostatic Neoplasms
Cyclodextrins
Neoplasms
43 Citations (Scopus)

NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., Margolin, K. A., Michaelson, M. D., Motzer, R. J., Pili, R., Roethke, S. & Srinivas, S., 2011, In : JNCCN Journal of the National Comprehensive Cancer Network. 9, SUPPL. 1

Research output: Contribution to journalArticle

Molecular Targeted Therapy
Advisory Committees
Renal Cell Carcinoma
Therapeutics
32 Citations (Scopus)

Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: An illustration with the Supportive Care Needs Survey and the QLQ-C30

Snyder, C. F., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Aug 2010, In : Quality of Life Research. 19, 6, p. 837-845 9 p.

Research output: Contribution to journalArticle

Needs Assessment
ROC Curve
Area Under Curve
Aptitude
Fatigue
23 Citations (Scopus)

Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells

Pettazzoni, P., Ciamporcero, E., Medana, C., Pizzimenti, S., Dal Bello, F., Minero, V. G., Toaldo, C., Minelli, R., Uchida, K., Dianzani, M. U., Pili, R. & Barrera, G., Oct 15 2011, In : Free Radical Biology and Medicine. 51, 8, p. 1610-1618 9 p.

Research output: Contribution to journalArticle

Metabolism
Prostatic Neoplasms
Cells
4-hydroxy-2-nonenal
Detoxification
1659 Citations (Scopus)

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. & Figlin, R. A., Aug 1 2009, In : Journal of Clinical Oncology. 27, 22, p. 3584-3590 7 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Interferon-alpha
Survival
Disease-Free Survival
Hand-Foot Syndrome

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors

Scognamiglio, G., De Chiara, A., Parafioriti, A., Armiraglio, E., Fazioli, F., Gallo, M., Aversa, L., Camerlingo, R., Cacciatore, F., Colella, G., Pili, R. & de Nigris, F., Jan 1 2019, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journalArticle

Open Access
Organoids
Neoplasms
CD8-Positive T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Chordoma
28 Citations (Scopus)

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

Koskimaki, J. E., Karagiannis, E. D., Tang, B. C., Hammers, H., Watkins, D. N., Pili, R. & Popel, A. S., Feb 1 2010, In : BMC Cancer. 10, 29.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Heterografts
Collagen
Peptides
Growth
15 Citations (Scopus)

Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial

Armstrong, A. J., Anand, A., Edenbrandt, L., Bondesson, E., Bjartell, A., Widmark, A., Sternberg, C. N., Pili, R., Tuvesson, H., Nordle, Ö., Carducci, M. A. & Morris, M. J., Jul 1 2018, In : JAMA oncology. 4, 7, p. 944-951 8 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Randomized Controlled Trials
Biomarkers
Bone and Bones
164 Citations (Scopus)

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., Enas, N., Sinha, V., Thornton, D. E. & Herbst, R. S., Sep 1 2006, In : Journal of Clinical Oncology. 24, 25, p. 4092-4099 8 p.

Research output: Contribution to journalArticle

Protein Kinase C beta
Pharmacokinetics
Neoplasms
Maximum Tolerated Dose
Head and Neck Neoplasms
14 Citations (Scopus)

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma

Sinibaldi, V. J., Elza-Brown, K., Schmidt, J., Eisenberger, M. A., Rosenbaum, E., Denmeade, S. R., Pili, R., Walczak, J., Baker, S. D., Zahurak, M. & Carducci, M. A., Aug 2006, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 29, 4, p. 395-398 4 p.

Research output: Contribution to journalArticle

docetaxel
Androgens
Prostate
Carcinoma
Prostatic Neoplasms
152 Citations (Scopus)

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

Pili, R., Hag̈gman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Bjor̈k, A., Nordle, O., Forsberg, G., Carducci, M. A. & Armstrong, A. J., Oct 20 2011, In : Journal of Clinical Oncology. 29, 30, p. 4022-4028 7 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Placebos
Castration
Disease-Free Survival
Neoplasm Metastasis
3 Citations (Scopus)

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Monk, P., Liu, G., Stadler, W. M., Geyer, S., Huang, Y., Wright, J., Villalona-Calero, M., Wade, J., Szmulewitz, R., Gupta, S., Mortazavi, A., Dreicer, R., Pili, R., Dawson, N., George, S. & Garcia, J. A., Jan 1 2018, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Disease-Free Survival
Proto-Oncogene Proteins c-met
34 Citations (Scopus)

Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse After Definitive Radical Retropubic Prostatectomy or Radiotherapy

Bajaj, G. K., Zhang, Z., Garrett-Mayer, E., Drew, R., Sinibaldi, V., Pili, R., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A. & DeWeese, T. L., Mar 2007, In : Urology. 69, 3, p. 526-531 6 p.

Research output: Contribution to journalArticle

Prostatectomy
Prostatic Neoplasms
Radiotherapy
Recurrence
Prostate-Specific Antigen
46 Citations (Scopus)

Phase II study on the addition of ASA404 (vadimezan; 5,6- dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

Pili, R., Rosenthal, M. A., Mainwaring, P. N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S. & Clingan, P., May 15 2010, In : Clinical Cancer Research. 16, 10, p. 2906-2914 9 p.

Research output: Contribution to journalArticle

vadimezan
docetaxel
Castration
Prostatic Neoplasms
Prostate-Specific Antigen
20 Citations (Scopus)

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

Rathkopf, D., Carducci, M. A., Morris, M. J., Slovin, S. F., Eisenberger, M. A., Pili, R., Denmeade, S. R., Kelsen, M., Curley, T., Halter, M., Collins, C., Fleisher, M., Heller, G., Baker, S. D. & Scher, H. I., 2008, In : Journal of Clinical Oncology. 26, 18, p. 2959-2965 7 p.

Research output: Contribution to journalArticle

docetaxel
Androgens
Prostatic Neoplasms
Testosterone
Leuprolide
3 Citations (Scopus)

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

Wentink, M. Q., Verheul, H. M. W., Pal, S. K., George, S., Voortman, J., Danchaivijitr, P., Adelaiye, R., Poslinski, D., Groman, A., Hutson, A. & Pili, R., 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Dalteparin
Renal Cell Carcinoma
Factor Xa
Therapeutics
Low Molecular Weight Heparin
104 Citations (Scopus)

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

Siu, L. L., Pili, R., Duran, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., Li, Z., Kalita, A. M., Laille, E. J., Besterman, J. M., Martell, R. E. & Carducci, M. A., 2008, In : Journal of Clinical Oncology. 26, 12, p. 1940-1947 8 p.

Research output: Contribution to journalArticle

Histones
Neoplasms
Pharmacokinetics
Acetylation
Beverages
95 Citations (Scopus)

Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A. & Rudek, M. A., Jan 3 2012, In : British Journal of Cancer. 106, 1, p. 77-84 8 p.

Research output: Contribution to journalArticle

NSC 153174
Isotretinoin
Histone Deacetylase Inhibitors
Tretinoin
Neoplasms

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

Wood, A., George, S., Adra, N., Chintala, S., Damayanti, N. & Pili, R., Jan 1 2019, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
MicroRNAs
Renal Cell Carcinoma
Maximum Tolerated Dose
Everolimus
3 Citations (Scopus)

Phase I trials of anti-ENPP3 antibody–drug conjugates in advanced refractory renal cell carcinomas

Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., Reyno, L., Wiseman, A., Trave, F., Anand, B., Morrison, K., Doñate, F. & Kollmannsberger, C. K., Sep 15 2018, In : Clinical Cancer Research. 24, 18, p. 4399-4406 8 p.

Research output: Contribution to journalArticle

Pyrophosphatases
Phosphoric Diester Hydrolases
Renal Cell Carcinoma
Hybridomas
Cricetulus
81 Citations (Scopus)

Platelets take up the monoclonal antibody bevacizumab

Verheul, H. M. W., Lolkema, M. P. J., Qian, D. Z., Hilkes, Y. H. A., Liapi, E., Akkerman, J. W. N., Pili, R. & Voest, E. E., Sep 15 2007, In : Clinical Cancer Research. 13, 18, p. 5341-5347 7 p.

Research output: Contribution to journalArticle

Blood Platelets
Monoclonal Antibodies
Vascular Endothelial Growth Factor A
Fluorescein-5-isothiocyanate
Bevacizumab
22 Citations (Scopus)

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acidin cancer patients

Li, J., Jameson, M. B., Baguley, B. C., Pili, R. & Baker, S. D., Apr 1 2008, In : Clinical Cancer Research. 14, 7, p. 2102-2110 9 p.

Research output: Contribution to journalArticle

Acetic Acid
Blood Vessels
Pharmacokinetics
Population
Neoplasms
11 Citations (Scopus)

Posttranscription regulation of prostate cancer growth

Shen, L. & Pili, R., Jan 2008, In : Cancer journal (Sudbury, Mass.). 14, 1, p. 46-53 8 p.

Research output: Contribution to journalReview article

Prostatic Neoplasms
Growth
Proteins
Histone Deacetylase Inhibitors
Androgen Receptors
15 Citations (Scopus)

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Pili, R., Sinibaldi, V. J., Walczak, J. S. & Denmeade, S. R., Sep 2007, In : Cancer Biology and Therapy. 6, 9, p. 1360-1367 8 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Phosphotransferases
Therapeutics
Prostate
Prostatectomy
3 Citations (Scopus)

Pre-clinical models of renal carcinoma and their utility in drug development

Salumbides, B. C., Lehet, K. M., Ndikuyeze, G. & Pili, R., 2009, In : Current Protocols in Pharmacology. SUPPL.47

Research output: Contribution to journalReview article

Kidney Neoplasms
Carcinoma
Kidney
Renal Cell Carcinoma
Pharmaceutical Preparations
28 Citations (Scopus)

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Pokuri, V. K., Syed, J. R., Yang, Z., Field, E. P., Cyriac, S., Pili, R., Levine, E. G., Azabdaftari, G., Trump, D. L., Guru, K. & George, S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. e59-e65

Research output: Contribution to journalArticle

Urinary Bladder
Carcinoma
Drug Therapy
Muscles
Cystectomy
3 Citations (Scopus)
Genetic Heterogeneity
Fluorescence In Situ Hybridization
Renal Cell Carcinoma
Neoplasms
Chromosome Deletion
62 Citations (Scopus)

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Pili, R., Sinibaldi, V., Carducci, M. A., Hammers, H., Eisenberger, M. A. & Sella, A., 2012, In : Oncologist. 17, 12, p. 1508-1514 7 p.

Research output: Contribution to journalArticle

Nomograms
Ketoconazole
Castration
Prostatic Neoplasms
Neutrophils
36 Citations (Scopus)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R. & Rustum, Y. M., Jul 17 2012, In : BMC Cancer. 12, 293.

Research output: Contribution to journalArticle

Prolyl Hydroxylases
Hypoxia-Inducible Factor 1
Selenium
Renal Cell Carcinoma
Growth
30 Citations (Scopus)

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth

Deng, X., Shao, G., Zhang, H. T., Li, C., Zhang, D., Cheng, L., Elzey, B. D., Pili, R., Ratliff, T. L., Huang, J. & Hu, C. D., Aug 22 2016, (Accepted/In press) In : Oncogene.

Research output: Contribution to journalArticle

Protein-Arginine N-Methyltransferases
Androgen Receptors
Epigenomics
Prostatic Neoplasms
Growth
2 Citations (Scopus)

Provenge: Combating prostate cancer with a vengeance?

Schwaab, T. & Pili, R., Aug 2011, In : Expert Review of Vaccines. 10, 8, p. 1113-1114 2 p.

Research output: Contribution to journalEditorial

Cancer Vaccines
Tissue Extracts
Immunomodulation
Immunotherapy
Prostatic Neoplasms
1 Citation (Scopus)

Psychological status, life and social conditions: A study in a population of institutionalized elderly people

Bartoloni, C., Guidi, L., di Giovanni, A. L., Antico, L., Cursi, F., Pili, R., Tricerri, A., Janiri, L., Mannelli, P., Pariante, C., Menini, E., Carbonin, P. & Gambassi, G., 1993, In : International Journal of Geriatric Psychiatry. 8, 5, p. 419-426 8 p.

Research output: Contribution to journalArticle

Social Conditions
Psychology
Hydrocortisone
Population
Institutionalization